1. main-0269
Diabetes Herbal Medicine BLOCKBUSTER Formulation Of 16 Anti Diabetic Herbs
e. g. , "gun control" 11. wire (USA)-June 10, 2008 Results From One-Year Study Suggest Advair(R) Provides
Important Benefits for African American Patients With Asthma, Results Suggested Improvements in Several
Endpoints for Advair Diskus(R) Compared to ICS Alone PRNewswire--African American patients with asthma
treated with Advair Diskus, a combination of the long-acting beta-agonist (LABA) salmeterol and the inhaled
corticosteroid (ICS) fluticasone propionate, had a lower rate of exacerbations when compared with patients who
received treatment with the ICS Flovent Diskus(R) (fluticasone propionate inhalation powder) alone, although the
difference was not statistically significant. Patients in the Advair group also showed improvements in lung...... . New
York Times, The (NY)-December 6, 2008 Warning Given on Use of 4 Popular Asthma Drugs, but Debate Remains
Two federal drug officials have concluded that asthma sufferers risk death if they continue to use four hugely
popular asthma drugs--Advair, Symbicort, Serevent and Foradil. But the officials' views are not universally shared
within the government. The two officials, who work in the safety division of the Food and Drug Administration, wrote
in an assessment on the agency's Web site on Friday that asthma sufferers of all ages should no longer take the
medicines. ...... a. wire (USA)-April 30, 2008 FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in
Patients With COPD, Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations and
Improve Lung Function PRNewswire-FirstCall--The U. S. Food and Drug Administration today approved Advair
Diskus(R) 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of
exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations.
With this approval, Advair becomes the only treatment FDA has approved to reduce COPD exacerbations.
Treatment guidelines for COPD state that the reduction of exacerbations is a key goal in...... . wire (USA)-May 1,
2008 FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD, Advair 250/50 Now
the Only Treatment Approved to Both Reduce Exacerbations and Improve Lung Function PRNewswire-FirstCall--
Late yesterday the U. S. Food and Drug Administration approved Advair Diskus(R) 250/50 (fluticasone propionate
250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of exacerbations in patients with chronic
obstructive pulmonary disease (COPD) who have a history of exacerbations. With this approval, Advair becomes
the only treatment FDA has approved to reduce COPD exacerbations. Treatment guidelines for COPD state that
the reduction of exacerbations is a key...... . wire (USA)-May 1, 2008 FDA Approves Advair(R) 250/50 for
Reduction of Exacerbations in Patients With COPD, Advair 250/50 Now the Only Treatment Approved to Both
Reduce Exacerbations and Improve Lung Function PRNewswire-FirstCall--Late yesterday the U. S. Food and Drug
Administration approved Advair Diskus(R) 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg
inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease
(COPD) who have a history of exacerbations. With this approval, Advair becomes the only treatment FDA has
approved to reduce COPD exacerbations. Treatment guidelines for COPD state that the reduction of
exacerbations is a key...... . Orlando Sentinel, The (FL)-March 7, 2006 Asthma drugs get stronger warnings The
revised labels on Advair and Serevent warn of an increased risk of death. WASHINGTON--The asthma medication
Advair and a related drug will bear stronger warnings of an increased risk of death associated with one of their
ingredients. The revised warnings apply to Advair and Serevent, Food and Drug Administration spokeswoman
Laura Alvey said Monday. Advair is GlaxoSmithKline's best-selling product, and Serevent is another of the British
company's drugs. The updated versions of the "black-box" warnings on both...... . wire (USA)-October 29, 2008
Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with
COPD-Study showed no consistent differences in bone mineral density at the lumbar spine and total hip between
Advair Diskus 250/50 (fluticasone propionate and salmeterol inhalation powder) and salmeterol-Study provides
support for long term use of...... . wire (USA)-May 18, 2008 Patients With Asthma and Seasonal Allergies Respond
Better to Advair(R) for Their Asthma Than Singulair(TM), Study Suggests that Adding Singulair to Advair Offers no
Additional Improvement in Overall Asthma Control PRNewswire-FirstCall--Patients with both asthma and allergic
rhinitis, or seasonal allergies, experience significantly better lung function when treated with Advair Diskus(R)
(fluticasone propionate and salmeterol inhalation powder) as compared with Singulair (montelukast sodium). The
results of the 660-subject study were presented today at the International Conference of the American Thoracic
Society meeting in Toronto. The study also showed patients treated with Advair plus...... . wire (USA)-October 11,
2006 GSK Submits Supplemental Drug Application for Advair in COPD, Study results showed reduction in risk of
death and rate of exacerbations from life-threatening lung disease PRNewswire--GlaxoSmithKline announced
today that it has submitted a supplemental new drug application to the FDA to expand labeling for Advair Diskus(R)
(fluticasone propionate and salmeterol inhalation powder) based on results from TORCH, a three year study that
showed a reduction in the risk of death and the rate of COPD exacerbations, and other supporting studies. COPD,
or chronic obstructive pulmonary disease, is a complex lung disease that results in a progressive decline in lung......
. Datamonitor-May 19, 2008 GlaxoSmithKline's Advair reduces exacerbations in COPD patients GlaxoSmithKline
has reported that the use of its Advair Diskus 250/50 demonstrated a 30% reduction in exacerbations in patients
with chronic obstructive pulmonary disease who have a history of exacerbations as compared with salmeterol
alone. The randomized study of 797 patients was a replicate study which found that after a year of treatment,
patients treated with Advair Diskus 250/50 had a 30% reduction in the rate of annual exacerbations compared to
salmeterol......
Diabetes Herbal Medicine BLOCKBUSTER Formulation Of 16 Anti Diabetic Herbs